Authored By: Sarah
22 Aug 2024

Inflammatory Bowel Disease Market Size to grow by USD 7615.7 million between 2024-2028

Technavio, a leading provider of market research reports, has released its latest study on Inflammatory Bowel Disease Market. This report offers a comprehensive analysis of the current market trends, emerging opportunities, and key challenges.

Key Highlights:

  • Market Research Overview: In the inflammatory bowel disease market, the aging population is a significant growth driver. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to be over 60 years old, leading to a substantial increase in the prevalence of inflammatory bowel diseases. This demographic shift will fuel market expansion in the pharmaceuticals sector, focusing on research and development or production of drugs for this condition. Technavio's market analysis for the global healthcare industry includes the inflammatory bowel disease market, which is calculated based on the combined revenue generated by manufacturers and providers of pharmaceutical solutions for this condition. - The Inflammatory Bowel Disease Market is experiencing significant growth, fueled by the Increasing incidence of IBD worldwide. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

  • Major Findings:
    • Increasing incidence of IBD worldwide
    • Increasing demand for biologics and targeted therapies
    • High cost of IBD therapeutics
    • Adverse effects associated with drugs used for treating IBD
  • Growth Projections

The market size is estimated to grow by USD 7615.7 million, at a CAGR of 5.48% during the forecast period. In the dynamic IBD market, vendors are investing heavily in research and development (R&D) to introduce innovative therapies, including small molecules and biologics. Notable product launches include Lupin's Mirabegron Extended-Release Tablets, approved by the US FDA in April 2024, and HUMIRA (Adalimumab), a TNF blocker, which received US FDA approval in February 2021. These advancements underscore the industry's commitment to delivering effective solutions for various IBDs.

For insights on company offerings- Request a sample report!

  • Regional Insights

The Inflammatory Bowel Disease market represents a significant business opportunity due to the rising prevalence of IBD and increasing awareness leading to early diagnosis. Key players are investing in research and development to launch innovative treatments, while strategic collaborations and acquisitions expand their product portfolios. Market growth is driven by these factors, making it an attractive sector for investment.

About Technavio                                                                        

Technavio is a global market research company offering comprehensive reports and insights on various industries. Our research helps businesses make informed decisions by providing actionable data and trends. Technavio is based on four simple principles: easy-to-access reports, robust industry coverage, a focus on new and emerging technologies, and competitive pricing. We believe in helping companies and executives become better equipped to make faster, sounder, and more effective decisions. Technavio is one of the most influential market research and advisory firms in the world. We work with business and technology leaders to provide cutting-edge market research and insights to companies. 

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio